Therapeutic Drug Monitoring · 1997 · 19 citations · 13 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPediatric Clinical PharmacologyPharmacokinetic VariabilityPediatric PharmacokineticsPediatric PharmacologyPediatric Therapeutic Drug MonitoringPharmacokinetic SamplingPharmacokinetics In Children With CancerAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentChild PharmacokineticsClinic AttendanceMetabolite Pharmacokinetics
Measurement of red cell 6-mercaptopurine (MP) derived 6-thioguanine nucleotide (TGN) and methylmercaptopurine metabolites (MeMPs) can be used to monitor therapy in children who are administered MP for childhood lymphoblastic leukemia. Red cell TGNs are not influenced by the time of blood sampling in relation to the last MP dose. The purpose of this study was to find out whether the same is true for the MeMPs. Plasma MP and red cell MP metabolite pharmacokinetics were studied in seven children immediately before and for 4 hours after a protocol standardized dose of MP. Duplicate blood samples were taken, one was processed immediately whereas one was left at an ambient temperature for 24 hours. The variation in TGN and MeMP metabolites over the 0- to 4-hour period (10 time points per child) was within the error of the assays used. The coefficients of variation for the TGNs ranged from 2.7% to 7% and for the MeMPs, 4% to 10.7%. There was no difference in the TGN and MeMP concentrations measured when the blood samples were left for 24 hours. If a child takes a MP tablet immediately before a clinic appointment, it has no major influence on MeMP measurements.
13
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lynne Lennard, J S Lilleyman, Jon Van Loon et al. · The Lancet · 1990 · 659 citations
Variable Bioavailability of Oral Mercaptopurine
Solomon Zimm, Jerry M. Collins, Riccardo Riccardi et al. · New England Journal of Medicine · 1983 · 266 citations